Michael Levine
Internal Medicine · Woodmere, NYNPI 1942375126
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.5% of the total across 191 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 30 manufacturers, the largest accounting for just 17.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $843 and has fallen 63.1% since, to $311 in 2025.
Across 191 payments — averaging $18.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$615
- AstraZeneca$421
- Pfizer$317
- Amgen$237
- Novo Nordisk$236
- GSK$233
- plus $1K from 24 others
Across 1 payment — averaging $25,000 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$25K
What the payments were for
- Speaking & faculty fees$1254%
- Food & beverage$3,42096%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 36 | $615 |
| AstraZeneca | 24 | $421 |
| Pfizer | 17 | $317 |
| Amgen(2 entities) | 15 | $237 |
| Novo Nordisk | 14 | $236 |
| GSK | 13 | $233 |
| Johnson & Johnson(2 entities) | 7 | $216 |
| Merck | 8 | $133 |
| Lilly USA, LLC | 9 | $131 |
| Sanofi | 1 | $125 |
| Boehringer Ingelheim | 7 | $118 |
| Kowa Pharmaceuticals America, Inc. | 6 | $88 |
| Sanofi-aventis U.S. LLC | 4 | $79 |
| Esperion Therapeutics, Inc. | 1 | $77 |
| Heartflow, Inc. | 2 | $69 |
| Novartis | 4 | $67 |
| Astellas Pharma US Inc | 3 | $53 |
| Sanofi Pasteur Inc. | 3 | $47 |
| Amarin Pharma, Inc. | 3 | $46 |
| Amneal Pharmaceuticals LLC | 2 | $40 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $34 |
| Sumitomo Pharma America, Inc. | 2 | $33 |
| Medtronic | 1 | $27 |
| Circassia Inc. | 1 | $17 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $16 |
| Bayer | 1 | $16 |
| Bausch Health US, LLC | 1 | $15 |
| Almatica Pharma LLC | 1 | $14 |
| Bavarian Nordic A/s | 1 | $13 |
| Seqirus USA Inc | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,545 in reported general payments places this provider in the 85th percentile of 9,771 internal medicine providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 86 | $87,732 |
| OzempicSemaglutide | 62 | $61,384 |
| EliquisApixaban | 37 | $42,783 |
| XareltoRivaroxaban | 33 | $21,900 |
| JardianceEmpagliflozin | 15 | $12,026 |
| MyrbetriqMirabegron | 12 | $9,890 |
| Breo ElliptaFluticasone/Vilanterol | 13 | $7,525 |
| EdarbiAzilsartan Medoxomil | 17 | $5,887 |
| VyvanseLisdexamfetamine Dimesylate | 13 | $4,494 |
| Atorvastatin Calcium | 246 | $3,615 |
| Rosuvastatin Calcium | 176 | $3,020 |
| SynthroidLevothyroxine Sodium | 27 | $2,895 |
| PaxlovidNirmatrelvir/Ritonavir | 26 | $2,859 |
| Ezetimibe | 68 | $2,589 |
| Levothyroxine Sodium | 95 | $2,505 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro | $131 | $87,73286 claims |
| Novo NordiskOzempic | $236 | $61,38462 claims |
| PfizerEliquis, Paxlovid | $317 | $45,64263 claims |
| Johnson & JohnsonXarelto | $216 | $21,90033 claims |
| Boehringer IngelheimJardiance | $118 | $12,02615 claims |
| Astellas Pharma US IncMyrbetriq | $53 | $9,89012 claims |
| GSKBreo Ellipta | $233 | $7,52513 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Vyvanse | $34 | $4,49413 claims |
| AbbVieSynthroid | $615 | $2,89527 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $40 | $2,50595 claims |
| Almatica Pharma LLCSertraline Hcl | $14 | $79753 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 9,771 internal medicine providers in New York.
Other internal medicine in Woodmere
- David DoveEast Hampton$12.3M
- Bruce BergerBrooklyn$3.4M
- Nicholas RobinsonBuffalo$2.9M
- Stephen SaletanNew York$2.6M
- Ziad AliNew York$2M
- Scott BeegleAlbany$1.9M
- Anthony MartinezBuffalo$1.6M
- Javier MoralesGreenvale$1.3M
- Ricky HsuNew York$1M
- James UnderbergNew York$953K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.